A pivotal step in advancing comprehensive inpatient and outpatient diabetes care.
Seamlessly integrating Monarch’s specialized inpatient insulin dosing expertise.
Uniquely positioned to manage diabetes from hospital to home.
Enhanced care continuity, improved patient transitions, and optimized glycemic management.
Monarch’s EndoTool has consistently demonstrated significant clinical improvements:
1 Price C, Aloi J. Impact of Blood Glucose Target Ranges for IV Insulin Infusions on Inpatient Outcomes Using EndoTool IV. Poster presented at: American Diabetes Association (ADA) 84th Scientific Sessions; June 21–24, 2024; Orlando, FL.
2 Deines T, Hardee S, Chidester P, Improved Mortality, Length of Stay, and Cost of Care in DKA with The Use of a Computerized Dosing Algorithm. Poster presented at: American
Association of Clinical Endocrinology (AACE) Annual Meeting 2025 https://monarchmedtech.com/wp-content/uploads/2025/05/PMM-PS-079-AACE-Poster_2025-Rev-0.pdf
3 Scheid Z, Salim K, Gomes J, Abedeen D, Riaz R, Calderon Martinez E, Ortiz L, Schrader A, Helmuth A, Srivastav S, Chidester P, Atrash A. Utilization of a Computerized Dosing Algorithm
to Improve Management in Diabetic Ketoacidosis. UPMC-DST-Poster.pdf
“This acquisition represents a pivotal step in Glooko’s mission to transform diabetes management in every care setting. We’ve built a strong foundation in the outpatient space — simplifying diabetes management for clinicians through unified device integration, EHR connectivity, and actionable insights. By adding Monarch’s proven inpatient insulin dosing expertise, we’re now uniquely positioned to deliver a truly comprehensive hospital-to-home solution that can improve outcomes, streamline workflows, and enhance patient safety. Looking ahead, this platform also creates opportunities to extend our leadership into primary care and advanced glycemic management, enabling us to serve patients and providers across the full continuum of care.” — Mike Alvarez, CEO, Glooko